Grainne Mary O'KAne
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Grainne Mary O'KAne has a total of 591 co-authors. Here are the top co-authors by number of shared publications:
- Julie M. Wilson
PanCuRx Translational Research Initiative, Ontario institute for Cancer Research, Toronto, ON, Canada
83 shared publications - Steven Gallinger
Ontario Institute for Cancer Research, Toronto, Canada
75 shared publications - Robert E. Denroche
PanCuRx Translational Research Initiative, Ontario Institute for Cancer Research, Toronto, Ontario, Canada
73 shared publications - Amy Zhang
Ontario Institute for Cancer Research, Toronto, ON, Canada
72 shared publications - Chani Stossel
Oncology Institute, Sheba Medical Center, Tel Hashomer, Israel
64 shared publications - Maria Raitses-Gurevich
Oncology Institute, Sheba Medical Center, Tel Hashomer, Israel
64 shared publications
Latest Publications
- 5 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
Integrated Whole-Genome and Transcriptome Sequencing Reveals Divergent Evolutionary Processes Across Biliary Tract Cancer Subtypes
Biliary tract cancer (BTC) comprises a family of rare malignancies subclassified by anatomy and pathology. However, this classification scheme may obscure shared biology and limit patient stratification. Here, we tested whether BTC heterogeneity can be explained by coherent latent axes and evaluated the potential to unify diverse clinical and genomic factors under a tractable biological framework. Whole-genome and transcriptome sequencing was performed on 180 tumors enriched for tumor cells by laser capture microdissection to identify shared programs in BTC. Network integration across transcriptomic classes identified two consensus cancer subtypes (CCS). The CCS segregated with anatomical location of primary tumor, and gene expression marker analyses suggested that subtypes reflect tumor cell of origin differences. The CCS displayed strikingly divergent molecular landscapes, explaining more variance than anatomical location of the primary tumor. CCS-B tumors were mutationally loaded with clock-like and APOBEC signatures and extrachromosomal DNA, whereas CCS-A tumors were characterized by chromosome-arm deletions. This approach showed that harnessing the genomic and transcriptomic diversity of BTC provides insights into shared biology and improves stratification.
- 5 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
Integrated Whole-Genome and Transcriptome Sequencing Reveals Divergent Evolutionary Processes Across Biliary Tract Cancer Subtypes
Biliary tract cancer (BTC) comprises a family of rare malignancies subclassified by anatomy and pathology. However, this classification scheme may obscure shared biology and limit patient stratification. Here, we tested whether BTC heterogeneity can be explained by coherent latent axes and evaluated the potential to unify diverse clinical and genomic factors under a tractable biological framework. Whole-genome and transcriptome sequencing was performed on 180 tumors enriched for tumor cells by laser capture microdissection to identify shared programs in BTC. Network integration across transcriptomic classes identified two consensus cancer subtypes (CCS). The CCS segregated with anatomical location of primary tumor, and gene expression marker analyses suggested that subtypes reflect tumor cell of origin differences. The CCS displayed strikingly divergent molecular landscapes, explaining more variance than anatomical location of the primary tumor. CCS-B tumors were mutationally loaded with clock-like and APOBEC signatures and extrachromosomal DNA, whereas CCS-A tumors were characterized by chromosome-arm deletions. This approach showed that harnessing the genomic and transcriptomic diversity of BTC provides insights into shared biology and improves stratification.
- 1 November 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (11)
Impact of Clonal Hematopoiesis on Outcomes in Metastatic Pancreatic Ductal Adenocarcinoma: Analysis From the PASS-01 Trial
Purpose: Clonal hematopoiesis (CH) is increasingly recognized as a proinflammatory driver of adverse outcomes in solid tumors. Tumor-infiltrating immune cells with CH (TI-CH) actively promote tumor growth and those harboring TI-CH experience significantly worse survival. We investigated the prevalence and impact of CH on outcomes in patients with treatment-naïve metastatic pancreatic ductal adenocarcinoma (PDAC). Methods: Peripheral blood from 125 patients with metastatic PDAC enrolled in the PASS-01 trial (ClinicalTrials.gov identifier: NCT04469556 ) was evaluated. CH was defined as the presence of pathogenic or likely pathogenic variants with a variant allele frequency (VAF) of ≥1% in a 23 gene panel. Survival was estimated using the Kaplan-Meier method and compared using the log-rank test. Hazard ratios (HRs) were estimated using multivariable Cox proportional hazards regression. Results: CH was detected in 36.8% (46 of 125) of patients, and DNMT3A (60.9%) and TET2 (17.4%) were the most frequently mutated genes. There was no significant difference in progression-free survival (PFS; median, 4.9 v 5.2 months; HR, 1.01 [95% CI, 0.68 to 1.49]; P = .95) and overall survival (OS; median, 9.4 v 9.6 months; HR, 0.99 [95% CI, 0.63 to 1.53]; P = .95) between CH-positive and CH-negative patients, respectively. Among patients with basal-like subtype (n = 23), the presence of CH was associated with a numerically shorter PFS (median, 2.4 v 4.7 months; HR, 2.50 [95% CI, 0.93 to 6.84]; P = .06) and OS (median, 6.2 v 10.2 months; HR, 1.37 [95% CI, 0.51 to 3.69]; P = .52). In contrast, classical subtype showed no significant differences in survival outcomes by CH. Conclusion: CH is prevalent in metastatic PDAC but not independently prognostic. Further examination of CH in basal subtype tumors and the role of TI-CH in PDAC is needed.
- 1 November 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (11)
Impact of Clonal Hematopoiesis on Outcomes in Metastatic Pancreatic Ductal Adenocarcinoma: Analysis From the PASS-01 Trial
Purpose: Clonal hematopoiesis (CH) is increasingly recognized as a proinflammatory driver of adverse outcomes in solid tumors. Tumor-infiltrating immune cells with CH (TI-CH) actively promote tumor growth and those harboring TI-CH experience significantly worse survival. We investigated the prevalence and impact of CH on outcomes in patients with treatment-naïve metastatic pancreatic ductal adenocarcinoma (PDAC). Methods: Peripheral blood from 125 patients with metastatic PDAC enrolled in the PASS-01 trial (ClinicalTrials.gov identifier: NCT04469556 ) was evaluated. CH was defined as the presence of pathogenic or likely pathogenic variants with a variant allele frequency (VAF) of ≥1% in a 23 gene panel. Survival was estimated using the Kaplan-Meier method and compared using the log-rank test. Hazard ratios (HRs) were estimated using multivariable Cox proportional hazards regression. Results: CH was detected in 36.8% (46 of 125) of patients, and DNMT3A (60.9%) and TET2 (17.4%) were the most frequently mutated genes. There was no significant difference in progression-free survival (PFS; median, 4.9 v 5.2 months; HR, 1.01 [95% CI, 0.68 to 1.49]; P = .95) and overall survival (OS; median, 9.4 v 9.6 months; HR, 0.99 [95% CI, 0.63 to 1.53]; P = .95) between CH-positive and CH-negative patients, respectively. Among patients with basal-like subtype (n = 23), the presence of CH was associated with a numerically shorter PFS (median, 2.4 v 4.7 months; HR, 2.50 [95% CI, 0.93 to 6.84]; P = .06) and OS (median, 6.2 v 10.2 months; HR, 1.37 [95% CI, 0.51 to 3.69]; P = .52). In contrast, classical subtype showed no significant differences in survival outcomes by CH. Conclusion: CH is prevalent in metastatic PDAC but not independently prognostic. Further examination of CH in basal subtype tumors and the role of TI-CH in PDAC is needed.
- 11 August 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (8) , 2738-2740
From RAS inhibitor resistance to rational combination strategies
- 11 August 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (8) , 2738-2740
From RAS inhibitor resistance to rational combination strategies
- 23 July 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85 (4) , 740-752
Pushing the boundaries of liver resection for liver cancer
- 23 July 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85 (4) , 740-752
Pushing the boundaries of liver resection for liver cancer
- Open Access
- 20 July 2026
- Published by Springer Nature in Targeted Oncology
- Vol. 21 (4) , 521-540
Precision Medicine in Pancreatic Cancer: Targeting KRAS and Beyond
For the past decades, chemotherapy constituted the therapeutic foundation in advanced or metastatic pancreatic cancer. Despite significant advances in the molecular understanding, translation into tangible patient benefit has remained modest. Until recently, mutant KRAS, the dominant oncogenic driver, was considered undruggable, and only a small subgroup of patients potentially benefited from targeted therapies. With the emergence of KRAS inhibitors, most patients with pancreatic cancer in theory qualify for targeted therapeutics. Final results from the RASolute 302 trial showed clinically meaningful activity of RAS inhibition in patients with metastatic pancreatic cancer and paved the way for approval. Ongoing preclinical and coclinical studies have documented both intrinsic and acquired mechanisms of resistance to KRAS inhibition. Given the cellular plasticity seen in pancreatic cancer, the identification and anticipation of resistance mechanisms will be critical to exploit emerging therapeutic vulnerabilities through novel combination strategies. In view of the increasing number of trials and the growing body of evidence for targeted therapies, pancreatic cancer is entering a transitional phase in which precision oncology strategies must be redefined beyond rare molecular subgroups. In this review, we will briefly revisit targeted therapeutic approaches in pancreatic cancer to then discuss the clinical implications of genomic and transcriptomic heterogeneity in KRAS-mutant and KRAS wild-type disease. We will outline how our expanding biological insights into pancreatic cancer could inform combination and sequential therapeutic approaches.
- 20 July 2026
- Published by Springer Nature in Targeted Oncology
- Vol. 21 (4) , 521-540
Open AccessPrecision Medicine in Pancreatic Cancer: Targeting KRAS and Beyond
For the past decades, chemotherapy constituted the therapeutic foundation in advanced or metastatic pancreatic cancer. Despite significant advances in the molecular understanding, translation into tangible patient benefit has remained modest. Until recently, mutant KRAS, the dominant oncogenic driver, was considered undruggable, and only a small subgroup of patients potentially benefited from targeted therapies. With the emergence of KRAS inhibitors, most patients with pancreatic cancer in theory qualify for targeted therapeutics. Final results from the RASolute 302 trial showed clinically meaningful activity of RAS inhibition in patients with metastatic pancreatic cancer and paved the way for approval. Ongoing preclinical and coclinical studies have documented both intrinsic and acquired mechanisms of resistance to KRAS inhibition. Given the cellular plasticity seen in pancreatic cancer, the identification and anticipation of resistance mechanisms will be critical to exploit emerging therapeutic vulnerabilities through novel combination strategies. In view of the increasing number of trials and the growing body of evidence for targeted therapies, pancreatic cancer is entering a transitional phase in which precision oncology strategies must be redefined beyond rare molecular subgroups. In this review, we will briefly revisit targeted therapeutic approaches in pancreatic cancer to then discuss the clinical implications of genomic and transcriptomic heterogeneity in KRAS-mutant and KRAS wild-type disease. We will outline how our expanding biological insights into pancreatic cancer could inform combination and sequential therapeutic approaches.
- Open Access
Transcriptomic, Genomic, and Clinical Characterization of Morphological Classes in Localized and Metastatic Pancreatic Cancer
Background: Histomorphology is a strong prognostic biomarker correlated with basal-like and classical programs in surgically resected pancreatic ductal adenocarcinoma (PDAC). However, the spectrum of morphology and its biological associations remain poorly defined in advanced disease. Objectives: We explored the transcriptomic and genomic underpinnings and clinical relevance of morphological classes across localized and metastatic PDAC. Design: We unified morphological classifications into four classes: glandular, cribriform, solid, and squamous. We integrated transcriptome and whole–genome sequencing following laser–capture microdissection with morphological classifications in 348 PDAC patients, where half of the cohort included locally advance and metastatic stages to uncover molecular associations. Results: Non–glandular morphologies comprised three distinct classes that were enriched in metastatic disease. Transcriptomic profiling exhibited that glandular tumours predominantly expressed classical epithelial programs, although a subset displayed partial or full epithelial–mesenchymal transition signatures. In contrast, non–glandular morphologies showed basal–like transcriptional programs with subtype–specific pathways, including ciliogenesis in cribriform tumours, extracellular matrix remodelling and immune evasion in solid tumours, and keratinisation programs in squamous tumours. The solid class was significantly enriched in liver metastatic lesions and was associated with increased intra– tumoural morphological heterogeneity, whole-genome doubling, KRAS major allelic imbalance, and elevated KRAS–ERK signalling. Conclusion: Non–glandular morphologies identify biologically distinct PDAC tumor states that are enriched in liver metastases and associated with subtype–specific transcriptional programs and KRAS–driven genomic alterations.
Open AccessTranscriptomic, Genomic, and Clinical Characterization of Morphological Classes in Localized and Metastatic Pancreatic Cancer
Background: Histomorphology is a strong prognostic biomarker correlated with basal-like and classical programs in surgically resected pancreatic ductal adenocarcinoma (PDAC). However, the spectrum of morphology and its biological associations remain poorly defined in advanced disease. Objectives: We explored the transcriptomic and genomic underpinnings and clinical relevance of morphological classes across localized and metastatic PDAC. Design: We unified morphological classifications into four classes: glandular, cribriform, solid, and squamous. We integrated transcriptome and whole–genome sequencing following laser–capture microdissection with morphological classifications in 348 PDAC patients, where half of the cohort included locally advance and metastatic stages to uncover molecular associations. Results: Non–glandular morphologies comprised three distinct classes that were enriched in metastatic disease. Transcriptomic profiling exhibited that glandular tumours predominantly expressed classical epithelial programs, although a subset displayed partial or full epithelial–mesenchymal transition signatures. In contrast, non–glandular morphologies showed basal–like transcriptional programs with subtype–specific pathways, including ciliogenesis in cribriform tumours, extracellular matrix remodelling and immune evasion in solid tumours, and keratinisation programs in squamous tumours. The solid class was significantly enriched in liver metastatic lesions and was associated with increased intra– tumoural morphological heterogeneity, whole-genome doubling, KRAS major allelic imbalance, and elevated KRAS–ERK signalling. Conclusion: Non–glandular morphologies identify biologically distinct PDAC tumor states that are enriched in liver metastases and associated with subtype–specific transcriptional programs and KRAS–driven genomic alterations.
- 3 March 2026
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 23 (6) , 425-440
Perioperative approaches for patients with biliary tract cancer
Biliary tract cancers, encompassing intrahepatic, perihilar and distal cholangiocarcinoma and gallbladder cancer, are a heterogeneous group of highly aggressive malignancies. Most patients have unresectable disease at first presentation, and even those who undergo surgery are likely to have disease recurrence. Newer approaches have included liver transplantation for selected patients, and the integration of locoregional and systemic therapies has expanded the number of patients who can benefit from surgery. The advent of immune-checkpoint inhibitors and targeted therapies for patients with advanced-stage disease has prompted the exploration of these agents in earlier-stage disease settings. Despite this progress, treatment algorithms remain complex, necessitating a multidisciplinary and individualized approach to patient management. Future research should focus on optimizing patient selection through biomarker-driven strategies, including the integration of molecular profiles to guide the selection of systemic therapy, as well as refining the criteria for surgery and transplantation. These improvements will require global collaboration and novel clinical trial designs. In this Review, we describe evolving perioperative strategies for the management of patients with biliary tract cancers and highlight emerging directions in the field.
- 3 March 2026
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 23 (6) , 425-440
Perioperative approaches for patients with biliary tract cancer
Biliary tract cancers, encompassing intrahepatic, perihilar and distal cholangiocarcinoma and gallbladder cancer, are a heterogeneous group of highly aggressive malignancies. Most patients have unresectable disease at first presentation, and even those who undergo surgery are likely to have disease recurrence. Newer approaches have included liver transplantation for selected patients, and the integration of locoregional and systemic therapies has expanded the number of patients who can benefit from surgery. The advent of immune-checkpoint inhibitors and targeted therapies for patients with advanced-stage disease has prompted the exploration of these agents in earlier-stage disease settings. Despite this progress, treatment algorithms remain complex, necessitating a multidisciplinary and individualized approach to patient management. Future research should focus on optimizing patient selection through biomarker-driven strategies, including the integration of molecular profiles to guide the selection of systemic therapy, as well as refining the criteria for surgery and transplantation. These improvements will require global collaboration and novel clinical trial designs. In this Review, we describe evolving perioperative strategies for the management of patients with biliary tract cancers and highlight emerging directions in the field.
- Top Cited Papers
- 11 February 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (26) , 2496-2506
Development and Validation of a Computational Histology Artificial Intelligence–Powered Predictive Biomarker for Selection of Chemotherapy in Advanced Pancreatic Cancer
PURPOSE: Predictive biomarkers to guide selection of first-line chemotherapy for advanced pancreatic ductal adenocarcinoma (PDAC) are an unmet clinical need. This study used the Computational Histology Artificial Intelligence (CHAI) platform to develop and validate a histomorphology-based G-chemo versus F-chemo (GvF) biomarker that predicts benefit from first-line fluoropyrimidine-based (F-chemo) versus gemcitabine-based (G-chemo) regimens. METHODS: The CHAI platform extracted quantitative histomorphologic features from whole-slide images of hematoxylin and eosin–stained diagnostic biopsies. In a multi-institutional development cohort, features associated with differential outcomes as measured by time to next treatment or death (TNTD) between F-chemo–treated and G-chemo–treated patients produced continuous biomarker scores, which were dichotomized into G-pref or F-pref results. The biomarker and threshold were locked. An independent validation cohort from the prospective COMPASS and Know Your Tumor studies assessed differential treatment outcomes by TNTD and overall survival (OS). RESULTS: There were 477 patients (development: 178; validation: 299). In validation, among 173 F-pref patients, those treated with F-chemo had significantly better outcomes than G-chemo for both TNTD ( P = .035; median TNTD: F-chemo 8.6 months; G-chemo 7.5 months) and OS ( P = .003; median OS: F-chemo 14.4 months; G-chemo 11.7 months). Among 126 G-pref patients, G-chemo had significantly superior TNTD ( P = .038; median TNTD: F-chemo 7.2 months; G-chemo 9.6 months), but no difference in OS ( P = .5; median OS: F-chemo 12.4 months; G-chemo 14.3 months). In propensity score–weighted analysis, the biomarker predicted treatment effect (biomarker-treatment interaction TNTD P < .001; OS P = .005). RNA subtypes were associated with TNTD and OS but did not predict differential treatment effects ( P = .3). CONCLUSION: The histomorphology-based GvF biomarker predicted differential treatment benefit of first-line GvF. This biomarker can guide optimal treatment selection for first-line therapy in advanced PDAC.
- 11 February 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (26) , 2496-2506
Top Cited PapersDevelopment and Validation of a Computational Histology Artificial Intelligence–Powered Predictive Biomarker for Selection of Chemotherapy in Advanced Pancreatic Cancer
PURPOSE: Predictive biomarkers to guide selection of first-line chemotherapy for advanced pancreatic ductal adenocarcinoma (PDAC) are an unmet clinical need. This study used the Computational Histology Artificial Intelligence (CHAI) platform to develop and validate a histomorphology-based G-chemo versus F-chemo (GvF) biomarker that predicts benefit from first-line fluoropyrimidine-based (F-chemo) versus gemcitabine-based (G-chemo) regimens. METHODS: The CHAI platform extracted quantitative histomorphologic features from whole-slide images of hematoxylin and eosin–stained diagnostic biopsies. In a multi-institutional development cohort, features associated with differential outcomes as measured by time to next treatment or death (TNTD) between F-chemo–treated and G-chemo–treated patients produced continuous biomarker scores, which were dichotomized into G-pref or F-pref results. The biomarker and threshold were locked. An independent validation cohort from the prospective COMPASS and Know Your Tumor studies assessed differential treatment outcomes by TNTD and overall survival (OS). RESULTS: There were 477 patients (development: 178; validation: 299). In validation, among 173 F-pref patients, those treated with F-chemo had significantly better outcomes than G-chemo for both TNTD ( P = .035; median TNTD: F-chemo 8.6 months; G-chemo 7.5 months) and OS ( P = .003; median OS: F-chemo 14.4 months; G-chemo 11.7 months). Among 126 G-pref patients, G-chemo had significantly superior TNTD ( P = .038; median TNTD: F-chemo 7.2 months; G-chemo 9.6 months), but no difference in OS ( P = .5; median OS: F-chemo 12.4 months; G-chemo 14.3 months). In propensity score–weighted analysis, the biomarker predicted treatment effect (biomarker-treatment interaction TNTD P < .001; OS P = .005). RNA subtypes were associated with TNTD and OS but did not predict differential treatment effects ( P = .3). CONCLUSION: The histomorphology-based GvF biomarker predicted differential treatment benefit of first-line GvF. This biomarker can guide optimal treatment selection for first-line therapy in advanced PDAC.
- 1 February 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (2) , e2500127
National Trends in Early-Onset Colorectal Cancer: Incidence and Challenges in the Republic of Ireland
PURPOSE: The incidence of early-onset colorectal cancer (EOCRC; CRC diagnosed before age 50 years) is increasing globally. This study analyses the trend in the Republic of Ireland over a 28-year period. METHODS: Epidemiologic data on CRC incidence were obtained from the National Cancer Registry of Ireland (NCRI) from January 1994 until December 2021. Additional information on age of diagnosis and tumor sidedness for the entire period was obtained, while data relating to stage and sex were available for the study period 1999-2018. Incidence rates were stratified by sex, age group (20-34, 35-49, and ≥ 50 years), and tumor location. RESULTS: Between 1994 and 2021, there were 61,180 cases of CRC among adults older than 20 years in the Republic of Ireland. The age-specific rate (ASPR) annual percentage change (APC) in patients younger than 50 years was 0.97 (95% CI, 0.30 to 1.76) in females and 0.57 (95% CI, 0.08 to 1.30) in males, while in patients age 50 years or older, it was –0.60 (95% CI, –1.03 to –0.15) in females and –0.70 in males (95% CI, –1.18 to –0.16), respectively. CONCLUSION: In line with global trends, the incidence of EOCRC is increasing in Ireland. Further studies investigating the etiology and optimal treatment strategies for this cohort are necessary.
- 1 February 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (2) , e2500127
National Trends in Early-Onset Colorectal Cancer: Incidence and Challenges in the Republic of Ireland
PURPOSE: The incidence of early-onset colorectal cancer (EOCRC; CRC diagnosed before age 50 years) is increasing globally. This study analyses the trend in the Republic of Ireland over a 28-year period. METHODS: Epidemiologic data on CRC incidence were obtained from the National Cancer Registry of Ireland (NCRI) from January 1994 until December 2021. Additional information on age of diagnosis and tumor sidedness for the entire period was obtained, while data relating to stage and sex were available for the study period 1999-2018. Incidence rates were stratified by sex, age group (20-34, 35-49, and ≥ 50 years), and tumor location. RESULTS: Between 1994 and 2021, there were 61,180 cases of CRC among adults older than 20 years in the Republic of Ireland. The age-specific rate (ASPR) annual percentage change (APC) in patients younger than 50 years was 0.97 (95% CI, 0.30 to 1.76) in females and 0.57 (95% CI, 0.08 to 1.30) in males, while in patients age 50 years or older, it was –0.60 (95% CI, –1.03 to –0.15) in females and –0.70 in males (95% CI, –1.18 to –0.16), respectively. CONCLUSION: In line with global trends, the incidence of EOCRC is increasing in Ireland. Further studies investigating the etiology and optimal treatment strategies for this cohort are necessary.